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SYNOPSIS 
This prospective cross-sectional study reports the repeatability of swept-source optical 
coherence tomography derived retinal and choroidal thickness measurements in eyes with 
neovascular age related macular degeneration. 
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ABSTRACT 
 
Background: The aim was to determine the intrasession repeatability of swept-source optical 
coherence tomography (SS-OCT) derived retinal and choroidal thickness measurements in 
eyes with neovascular age related macular degeneration (nAMD). 
Methods: A prospective study consisting of patients with active nAMD enrolled in the 
Distance of Choroid Study (DOCS) at Moorfields Eye Hospital, London.  Patients underwent 
three 12 x 9 mm macular raster scans using the DRI-OCT-1 SS-OCT (Topcon Inc.) device in 
a single imaging session. Retinal and choroidal thicknesses were calculated for the ETDRS 
(Early Treatment Diabetic Retinopathy Study) macular subfields. Repeatability was 
calculated according to methods described by Bland and Altman. 
Results: 39 eyes of 39 patients with nAMD were included with a mean (± SD) age of 73.9 (± 
7.2) years. The mean (± SD) retinal thickness of the central macular subfield was 225.7 μm 
(± 12.4 μm). The repeatability this subfield, expressed as a percentage of the mean central 
macular subfield thickness, was 23.2%. The percentage repeatability of the other macular 
subfields ranged from 13.2% to 28.7%. The intrasession coefficient of repeatability (CR) of 
choroidal thickness of the central macular subfield was 57.2 μm with a mean choroidal 
thickness (± SD) of 181μm (± 15.8 μm).  
Conclusions: This study suggests that a change greater than 23.2% of retinal thickness and 
57.2 μm choroidal thickness in the central macular subfield is required to distinguish true 
clinical change from measurement variability when using the DRI-OCT-1 device to manage 
patients with nAMD. 
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Abbreviations: 
AMD – age-related macular degeneration 
CI – confidence interval 
CNV – choroidal neovascularisation 
CR – coefficient of repeatability 
CV – coefficient of variation 
DOCS – Distance of Choroid Study 
ETDRS – Early Treatment Diabetic Retinopathy Study  
nAMD – neovascular age-related macular degeneration 
OCT – optical coherence tomography 
RPE – retinal pigment epithelium 
SD-OCT – spectral-domain optical coherence tomography 
SD – standard deviation 
SE – standard error 
SS-OCT – swept-source optical coherence tomography 
VA – visual acuity 
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INTRODUCTION 
 
Swept-source OCT (SS-OCT) is a recent development in OCT technology that has 
been recently introduced into clinical practice. SS-OCT utilises a tunable frequency light 
source that emits changing light frequencies over time measured by a photometer.[1] This, 
in combination with line scans averaging which improves the signal to noise ratio, leads to 
faster image acquisition and enhanced visualisation of retinal morphology. The DRI OCT-1 
(Topcon Inc.) incorporates this technology and the use of a long wavelength light source in 
this device (central wavelength of 1050 nm) theoretically enhances imaging of deeper 
structures including the choroid.[2]  
Macular thickness measurements for the various Early Treatment of Diabetic 
Retinopathy Study (ETDRS) subfields are derived using on-board automated segmentation 
software (Topcon Advanced Boundary Segmentation TABSTM).[3] Changes in macular 
thickness in eyes with neovascular age-related macular degeneration (nAMD) typically 
reflect disease activity, and this parameter has therefore become invaluable in guiding anti-
angiogenic treatment decisions both in clinical practice and in clinical trials.[4] Variation in 
the choroid may be associated with a range of macular conditions including pachychoroid 
and age related choroidopathy. [5, 6] OCT-derived subfoveal choroidal thickness 
measurements appear to be an important predictive factor in response to treatment with 
anti-angiogenic agents in eyes with nAMD.[7-9]. It has been suggested that the reported 
variation in choroidal thickness in patients with nAMD undergoing treatment with anti-
angiogenic agents indicates a potential role for this parameter in the assessment of disease 
activity and treatment response.[10]  
An understanding of the repeatability of OCT-derived macular thickness 
measurements is important in order to differentiate true clinical change from mere 
measurement variability. Definition of measurement repeatability using SS-OCT is essential 
to fully describe the value of this technology in nAMD. The potential role of SS-OCT 
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visualisation of the choroid in nAMD is being evaluated but description of thickness 
repeatability will help clinicians and researchers interpret clinical studies including those with 
anti-angiogenic agent. SS-OCT repeatability has been reported in normal subjects but there 
is potential for higher variability in patients with macular disease including nAMD. [11, 12]. 
Sources of measurement variability include, but are not limited to, automated inner and outer 
retinal boundary detection and segmentation errors, which are not uncommon when imaging 
eyes with nAMD and unstable fixation, resulting in variability in scan placement between 
consecutive scans.[13, 14]. This study estimates the repeatability of SS-OCT-derived retinal 
and choroidal thickness measurements in eyes with nAMD. 
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MATERIALS AND METHODS 
 
This study analysis forms part of the Distance of Choroid Study (DOCS). This was a 
prospective study evaluating the repeatability of a range of modalities imaging the posterior 
coats of the eye (sclera, choroid and retina). All participants provided written informed 
consent prior to commencement of the study. The study was approved by the local ethics 
committee (NRES Committee South East Coast – Surrey) and adhered to the tenet set forth 
in the Declaration of Helsinki. 
 
Study population 
Patients were identified from medical retina clinics at Moorfields Eye Hospital, 
London, United Kingdom. Subjects were eligible if aged between 50-90 years and had 
evidence of subfoveal CNV secondary to nAMD in at least 1 eye. Lesion size and type was 
assessed by fundus fluorescein angiography at presentation. If both eyes were eligible, the 
eye with the worse visual acuity was identified as the study eye. Subjects were required to 
be able to understand the nature of the study and be willing to undergo all the imaging 
investigations.  Exclusion criteria included other causes of CNV, media opacity precluding an 
adequate fundus view, previous ocular surgery (other than cataract surgery), and other 
significant ocular co-morbidity in the study eye. Patients with diabetes mellitus were also 
excluded from this study.  
 
SS-OCT imaging protocol 
After informed consent, medical history was obtained and best-corrected visual 
acuity (BCVA) measured. Subjects underwent three consecutive DRI-OCT-1 scans in a 
single imaging session by a clinical trials-certified technician. All subjects were adequately 
dilated prior to imaging with 1% tropicamide and 2.5% phenylephrine (Chauvin 
pharmaceuticals Ltd.). Each scan consisted of a 12 x 9 mm raster centered on the fovea. 
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Between scans, patients sat back away from the device and rested for a minimum of 1 
minute. The device was regularly serviced by a manufacturer-approved engineer.  
 
Analysis of macular retinal and choroidal thickness 
Retinal and choroidal thickness measurements of the nine ETDRS macular subfields 
were calculated using the on-board segmentation algorithm (TABSTM). The nine macular 
subfields are of 1mm (centre A1), 3mm (inner A2-5) and 6mm (A6-9) diameter centred on 
the fovea. The on-board segmentation algorithm defines the inner retinal boundary as the 
inner limiting membrane and the outer retinal boundary as the outer aspect of the retinal 
pigment epithelium (RPE)/Bruch’s membrane complex.[3] DRI OCT-1 images were directly 
visualised by an independent observer for automated segmentation error of retinal layers. 
This was defined as instances in which the software-determined retinal boundaries clearly 
deviated from true anatomical inner or outer retinal boundaries over a distance of 1mm or 
more (Figure 1). Patients were excluded if a segmentation error of greater than 1mm was 
present in the central macular subfield (A1) in any of the three SS-OCT images taken. [15] 
Similarly, segmentation error of choroidal layers was defined as instances in which the 
software determined choroidal boundaries clearly deviated by 1mm or more from the true 
anatomical boundaries (RPE/Bruch’s membrane and choroidal-scleral interface) and 
patients were excluded if this occurred in the central macular subfield in any of the three SS-
OCT choroidal images (Figure 2). [15] 
 
Statistical analyses 
Mean and standard deviation (SD) of retinal thickness for each of the nine macular 
subfields were calculated using Excel (Microsoft Excel for Mac 2011). Repeatability was 
calculated using methods described by Bland and Altman.[16] Briefly, each variable was 
confirmed to be normally distributed and the SD of each group of 3 measurements was 
plotted against the mean of those measurements in order to determine whether any 
variability was even in part related to the magnitude of the measurement (Pearson’s 
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correlation coefficient). The intra-subject standard deviation (Sw) was then calculated and the 
coefficient of repeatability (CR) was then calculated as 2x√(2×%&) or 2.77 x Sw. The width of 
the 95% confidence interval was calculated as 1.96 x Sw/√2(() − 1) where n = number of 
subjects and m = the number of repeated images, as described in previously completed 
analyses of CR in OCT measurements.[15] These analyses were also performed for 
choroidal thickness in each of the nine macular ETDRS subfields.  
If a significant relationship was found, the data was transformed logarithmically and 
the analysis repeated.[17] The intra-subject standard deviation (Sw) of logarithmically-
transformed data was calculated. The intra-subject coefficient of variation (CV) was 
calculated as the inverse logarithm of the intra-subject standard deviation minus 1 (CV = 
Inverse log10(Sw) -1). The repeatability of the mean retinal thickness measurement of each 
macular subfield was calculated as 2.77 x CV x 100%.[18] 
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RESULTS 
 
Subject Characteristics 
A total of 39 subjects were included in this study. Subject demographics and other 
characteristics are detailed in Table 1.  
Table 1:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 ETDRS – early treatment diabetic retinopathy study 
2 SD – standard deviation 
Patient characteristics  
Demographics 
Age (years) 
Gender (n %, total) 
    Male 
    Female 
Laterality (n, % total) 
    Left 
    Right 
Visual Acuity (ETDRS1 letter score) 
 
73.9 ± 7.2 
 
24 (61.5) 
15 (38.5) 
 
18  (46.2) 
21 (53.8) 
63.9 ± 18.5 
Lens status (n % total) 
   Phakic 
   Pseudophakic 
 
 
29 (74.4) 
10 (25.6) 
Lesion size (mean disc area ± SD2) 
 
1.2 ± 0.8 
Lesion type (n, % total) 
    Classic 
    Occult 
 
16 (41.0) 
23 (58.9) 
Anti-angiogenic treatment history(over 
previous 6 months) (n, % total) 
  
     Ranibizumab 
     Aflibercept 
     No previous treatment 
 
37 (94.9) 
 
30 (76.9) 
7 (17.9) 
2 (5.1) 
Mean number of intravitreal injections 
(over previous 6 months) 
2.5 
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Images were obtained between February 2014 and July 2014. The mean (± SD) age of 
the subjects in the study was 73.9 ± 7.2 years. Twenty-four subjects were male and 
there were 21 right eyes. Mean (± SD) BCVA was 63.9 (± 18.5) ETDRS letters. Thirty-
seven (94.9%) subjects had undergone treatment with anti-angiogenic agents within 
the previous 6 months. 
 
 
Retinal thickness measurements and repeatability 
 The mean (± SD) retinal thickness of the central macular subfield was 225.7 μm (± 
12.4 μm). The mean (± SD) retinal thicknesses of the nine macular subfields are shown in 
Table 2.  
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Table 2: 
 
 
 
 
 
 
 
 
ETDRS 
Macular 
subfield 
Scan 1 
retinal 
thicknes
s (μm) 
Scan 2 
retinal 
thickness 
(μm) 
Scan 3 
retinal 
thickness 
(μm) 
Mean retinal 
thickness  ± 
SD (μm) 
Difference 
between 
retinal 
thickness 
scans 
(ANOVA) 
Coefficient 
of 
variation 
(%) 
Repeatability 
(Percentage 
of mean 
retinal 
thickness) 
(%) 
A1 
central 
228.9 225.4 222.8 225.7 ± 12.4 0.827 8.4 23.2 
A2 inner 
superior 
256.0 256.3 255.8 256.1 ± 12.4 0.889 10.3 28.7 
A3 inner 
temporal 
257.0 261.7 258.4 259.1 ± 10.2 0.894 4.8 21.5 
A4 inner 
inferior 
258.6 258.6 260.2 259.1 ± 6.7 0.878 5.2 14.5 
A5 inner 
nasal 
256.5 259.7 262.8 259.4 ± 9.9 0.748 7.2 20.0 
A6 outer 
superior 
248.4 251.6 251.9 259.7 ± 7.8 0.850 5.3 14.7 
A7 outer 
temporal 
247.3 249.3 248.6 248.4 ± 10.2 0.881 6.3 14.4 
A8 outer 
inferior 
239.5 239.4 236.4 238.4 ± 6.1 0.868 5.6 15.5 
A9 outer 
nasal 
270.8 269.9 269.4 270.1 ± 8.1 0.868 4.8 13.2 
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Supplementary Figure 1a shows the relationship between the mean of the three repeated 
central macular subfield retinal thickness measurements and their SD, and demonstrates a 
degree of association between mean thickness and variability (Pearson’s product moment 
correlation coefficient r = 0.441; p=0.049 two-tailed t-test). Other macular subfields showed a 
similar degree of association between mean retinal thickness and variability. After 
logarithmic data transformation, however, there was no statistically significant relationship 
between mean retinal thickness and SD for any of the macular subfields (central macular 
subfield: Pearson’s product moment correlation coefficient r = 0.270; p = 0.097 two-tailed t-
test) (Supplementary Figure 1b). The percentage repeatability of the central macular subfield 
was 23.2%. The percentage repeatability of the nine ETDRS macular subfields ranged from 
13.2% to 28.7% (Table 2). 
 
Choroidal thickness measurements and repeatability 
Mean (± SD) of automated choroidal thickness of each of the nine ETDRS choroidal 
macular subfields is shown in Table 3.  
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Table 3:  
 
 
 
ETDRS Macular 
subfield 
Scan 1 
choroidal 
thickness 
(μm) 
Scan 2 
choroidal 
thickness (μm) 
Scan 3 
choroidal 
thickness 
(μm) 
Difference 
between 
choroidal 
thickness scans 
(ANOVA) 
Mean 
choroidal 
thickness  ± 
SD (μm) 
Coefficient of 
repeatability 
(95% CI) 
(μm) 
A1 central 180.9 180.7 180.9 0.988 180.9 ± 
14.7 
57.2 (55.5-
58.8) 
A2 inner 
superior 
180.3 182.3 188.8 0.866 183.8 ± 
12.9 
55.4 (53.8-
57.0) 
A3 inner 
temporal 
179.2 182.9 183.8 0.936 182.0 ± 
10.1 
41.9 (40.7-
43.1) 
A4 inner 
inferior 
158.7 164.2 163.3 0.934 162.1 ± 
12.5 
53.3 (51.8-
54.9) 
A5 inner 
nasal 
162.9 166.2 166.7 0.973 165.2 ± 
13.3 
60.3 (58.5-
62.0) 
A6 outer 
superior 
174.3 177.7 179.1 0.952 177.7 ± 8.5 40.3 (39.2-
41.5) 
A7 outer 
temporal 
170.4 171.8 172.0 0.989 171.4 ± 8.6 38.5 (37.4-
39.6) 
A8 outer 
inferior  
153.7 155.0 151.8 0.978 153.5 ± 
12.1 
55.9 (54.3-
57.5) 
A9 outer 
nasal 
143.0 140.3 140.6 0.984 141.3 ± 
13.0 
58.1 (56.4-
61.4) 
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The mean (± SD) choroidal thickness of the central macular subfield was 181 μm (±15.8 
μm). Supplementary Figure 1c shows the relationship between the automated mean 
choroidal thickness of the central macular subfield and the standard deviation of the 
measure. No correlation between the size of choroidal thickness measurements and the 
degree of variation was demonstrated (Pearson’s product moment correlation coefficient r = 
0.038; p = 0.820 two-tailed t-test). Plots for the other subfields similarly demonstrated no 
correlation. The coefficient of repeatability (CR) of choroidal thickness of the central macular 
subfield (A1) was 57.2 μm ((95% CI 55.5 - 58.8 μm). The CR of choroidal thickness of the 
other subfields ranged from 38.5 μm to 60.3 μm (Table 3). 
 
 
Automated segmentation error and visual acuity 
Manual assessment of all SS-OCT images showed that segmentation error of 
retinal layers in the central macular subfield in at least one SS-OCT image was present 
for 9 of 39 eyes (segmentation error rate 23.1%) (Figure 1) with a revised CR of 
23.0%. Segmentation error of choroidal layers was present in 10 out of 39 eyes 
(segmentation error rate 25.6%, Figure 2) with a revised CR of 47.3µm (45.7 – 
48.1 µm). 
 Supplementary Figure 2 shows the relationship between visual acuity 
measurements and the standard deviation of both repeated retina and choroidal 
thickness metrics of the central macular subfield demonstrating no significant 
relationship between visual acuity and retinal thickness (Pearson’s r = 0.05, p = 0.75 
paired T-test) and choroidal thickness (Pearson’s r = -0.09, p = 0.59 paired T-Test).  
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DISCUSSION 
 
 OCT-derived macular thickness measurements are used to assess disease activity 
thereby guiding treatment decisions in clinical practice, as well as forming outcome variables 
in clinical trials that evaluate anti-angiogenic agents for nAMD and other macular disorders 
[19-21]. SS-OCT has been recently introduced into clinical practice but little is known of the 
repeatability of SS-OCT-derived macular thickness measurements. Understanding the 
repeatability of retinal thickness measurements is essential for assessment of disease 
activity in nAMD. As we discover that changes in choroidal morphology and thickness may 
be associated with macular disease, it is increasingly important to differentiate between true 
clinical change and measurement variability. In this study, we determined the percentage 
repeatability of SS-OCT-derived central subfield retinal thickness to be 23.2%, indicating 
changes greater than 23.2% are required to support true clinical activity over simple 
measurement variability when using the DRI OCT-1 device.  Previous studies have 
evaluated the repeatability of both time-domain-derived and SD-OCT-derived retinal 
thickness measurements in nAMD, but to our knowledge, there are no previous reports 
investigating the repeatability of retinal thickness measurements in eyes with nAMD using a 
commercially available SS-OCT-based device. [22-24]  
After exclusion of patients with segmentation error in at least 1 SS-OCT scan, the 
revised percentage repeatability of the central macular subfield retinal thickness remained 
similar to the figure for the whole cohort (23.0%). This relatively modest improvement in 
repeatability after excluding eyes with segmentation error suggests that segmentation error 
is not a key factor contributing to measurement variability when using the DRI OCT-1 SS-
OCT device to image eyes with nAMD. Evaluation of the images of eyes without 
segmentation error but which displayed the most significant variability suggests that 
discrepancies in fixation stability between scans may have been important with some clear 
variation in ETDRS grid alignment (Supplementary Figure 3). This suggests that the addition 
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of eye tracking hardware/ software to maintain more precise alignment and registration of 
follow-up scans could potentially improve repeatability. Several factors have been 
associated with variation in fixation stability including visual acuity and alteration in macular 
structure.[25] Reduced visual acuity changes have been particularly associated with poor 
fixation stability in eyes with nAMD.[26] Intriguingly, there was no significant association 
between visual acuity and variability of retinal and choroidal thickness measurements in our 
study and this would suggest that determinants of fixation stability may include factors other 
than high-contrast distance visual acuity in eyes with nAMD.  
Evaluation of the clinical significance of SS-OCT derived choroidal thickness in 
patients with nAMD requires an appreciation of its measurement variability. Clinicians and 
researchers may elect to choose this newer technology particularly due to potentially deeper 
imaging penetration and its reliability in imaging deserve further scrutiny. We report an 
intrasession CR of the choroidal thickness of the central macular subfield using the DRI-
OCT-1 SS-OCT device as 57.2 μm (95% CI 55.5 - 58.8 μm). This suggests that a change in 
central subfield choroidal thickness of more than 57.2μm is necessary to suggest true 
clinical change rather than measurement variability in eyes with nAMD. The intrasession 
CRs of the choroidal thickness of the other macular subfields range from 38.5 μm to 60.3 
μm. To our knowledge, this is the first study reporting repeatability of SS-OCT derived 
choroidal thickness measurements in nAMD. Previous studies have reported a higher level 
of reproducibility of patients when measured manually in healthy patients, including a study 
at our institution, which suggested a CR of 34 μm using EDI spectral-domain OCT.[27] We 
note that our previous study investigating SD-OCT (Spectralis, Heidelberg, Heidelberg 
Engineering) repeatability in AMD reported a CR of 30.6 μm and 34.7 μm for retinal and 
choroidal thickness repeatability.[28] This suggests that SD-OCT may be more repeatable 
than macular thickness measurements taken in eyes with nAMD using SS-OCT. Whilst it 
appeared that segmentation error was not a significant factor in SS-OCT measurement 
repeatability, repeatability of SD-OCT retinal thickness measurements appeared to greatly 
improve after exclusion of eyes with segmentation error (13.7 μm). This suggests that 
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different factors underlie the variability encountered in nAMD eyes using these different 
imaging devices. 
There are several strengths and limitations of this study. This study was prospective 
in nature, thereby reducing inclusion / recruitment and reporting biases. Furthermore, the 
inclusion criteria likely reflected a real world cohort of patients attending hospital clinics for 
the treatment of nAMD. This study included 3 repeated measurements with a large sample 
size. A potential weakness of this study is that nAMD eyes with scans with segmentation 
error were not excluded from this study. However, this is likely to reflect real world data sets 
where segmentation error is a relatively common occurrence.[14] We attempted to address 
this potential limitation of the study by also providing a supplementary estimate of the 
repeatability of the central macular subfield after exclusion of subjects who had at least 1 
SS-OCT scan in which segmentation error occurred. Our analysis however was not 
corrected for change in fixation between scans and would likely have affected our 
repeatability estimates adversely. This does however also represent the real world clinical 
scenario arguably making our results more generalizable to a clinical setting. Retinal 
thickness measurements were transformed logarithmically to account for any variation 
associated with retinal thickness magnitude. It would be useful however to extend this study 
by assessment of patients with severe macular edema or atrophic change with disciform 
scar to assess any possible variation at extremes of macular thickness. 
 In summary, we report the intrasession percentage repeatability of retinal thickness 
of the central macular subfield as 23.2% and intrasession CR of choroidal thickness in the 
central subfield as 57.2μm using the DRI-OCT-1 SS-OCT. This study suggests a change of 
greater than 23.2% of retinal thickness and greater than 57.2μm of choroidal thickness in the 
central macular subfield is necessary to distinguish true clinical change from measurement 
variability in nAMD.  
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FIGURE LEGENDS 
Figure 1: Examples of DRI OCT-1 swept-source optical coherence tomography images 
with evidence of segmentation error affecting retinal layers of the central macular 
subfield. The automated software-determined retinal boundaries clearly deviate away from 
the true anatomical inner (inner limiting membrane) or outer (outer aspect of the 
RPE/Bruch’s membrane complex) retinal boundaries for at least 1mm in a tangential plane.  
 
Figure 2: Examples of DRI OCT-1 swept-source optical coherence tomography images 
with evidence of segmentation error affecting choroidal layers of the central macular 
subfield. The automated software-determined retinal boundaries clearly deviate away from 
the true anatomical inner (outer aspect of the RPE/Bruch’s membrane complex)) or outer 
(Haller’s layer) choroidal boundaries for at least 1mm in a tangential plane.  
 
Supplementary Figure 1: (A) Plot of mean and standard deviation central macula 
subfield (A1) thickness. There was statistically significant correlation between the 
mean thickness and the SD of the central macular subfield (Pearson’s r = 0.441; 
p=0.049 two-tailed t-test). (B) Plot of logarithmically transformed mean and 
standard deviation of central macular subfield (A1) retinal thickness. There was 
no statistically significant correlation when analysis was performed on logarithmically 
transformed data (r = 0.270; p =0.097 two tailed t-test) (C) Plot of mean and standard 
deviation of submacular choroidal thicknesss of the central macular subfield 
(A1). There was no statistically significant correlation between the mean choroidal 
thickness and the SD of the central macular subfield (r = 0.038; p = 0.820 two tailed t-
test) 
	 23	
 
Supplementary Figure 2: Correlation between visual acuity and macular thickness 
variability (A)plot of visual acuity ETDRS (Early Treatment Diabetic Retinopathy) letters and 
standard deviation of retinal thickness repeatability measurements, Pearson’s r = 0.05, p = 
0.75 two-tailed T-Test) (B) plot of visual acuity ETDRS letters and standard deviation of 
choroidal thickness repeatability measurements, Pearson’s r = -0.09, p = 0.59 two-tailed T-
Test)  
 
 
Supplementary Figure 3: Intrasession differences in software-determined ETDRS 
grid locations in neovascular age-related macular degeneration eyes using the 
DRI OCT-1 swept-source optical coherence tomography device. Three successive 
infrared fundus photographs with position of ETDRS grid for a patient representative of 
those displaying high variability in retinal thickness measurements. These images 
demonstrate intrasession variation in retinal thickness measurements within this eye; 
central macular subfield thicknesses were 191μm, 296μm, and 294μm in scans 1,2 
and 3, respectively. 
 
TABLE LEGENDS: 
Table 1: Subject characteristics of patients with neovascular age-related macular 
degeneration. 
Demographics (age, gender, laterality), lens status, lesion size and type and history of 
treatment with anti-vascular endothelial growth factor agents. 
Table 2: Retinal thickness metrics and intrasession repeatability in neovascular age-
related macular degeneration 
	 24	
Mean (±) standard deviation of mean retinal thickness of Early Treatment Diabetic 
Retinopathy Study macular subfields in three successive scans. No significant difference in 
mean retinal thickness was found between the mean retinal thickness of three repeated 
scans (one-way ANOVA). Intrasession repeatability of retinal thickness measurements of 
each macular subfield are shown. 
Table 3: Choroidal thickness metrics and intrasession coefficient of repeatability in 
neovascular age-related macular degeneration 
Mean (±) standard deviation of mean choroidal thickness of Early Treatment Diabetic 
Retinopathy Study submacular subfields in three successive scans. No significant difference 
in mean choroidal thickness was found between the mean choroidal thickness of three 
repeated scans (one-way ANOVA). Intrasession coefficient of repeatability of choroidal 
thickness measurements of each macular subfield are shown. 
 
 
